Literature DB >> 26509423

Chinese Herbal Formulas Si-Wu-Tang and Er-Miao-San Synergistically Ameliorated Hyperuricemia and Renal Impairment in Rats Induced by Adenine and Potassium Oxonate.

Yongping Guo, Qian Jiang, Dingkun Gui, Niansong Wang.   

Abstract

BACKGROUND/AIMS: Hyperuricemia is an independent risk factor for chronic kidney disease and cardiovascular disease. Here, we examined the combined protective effects of Chinese herbal formula Si-Wu-Tang and Er-Miao-San on hyperuricemia and renal impairment in rats.
METHODS: Rats were randomly divided into normal rats, hyperuricemic rats, and hyperuricemic rats orally administrated with benzbromarone (4.5 mg·kg⁻¹·d⁻¹), Si-Wu-Tang (3.78 g·kg⁻¹·d⁻¹) and Si-Wu-Tang plus Er-Miao-San (6.48 g·kg⁻¹·d⁻¹) for 4 weeks. Hyperuricemic rats were orally gavaged with adenine (0.1 g·kg⁻¹·d⁻¹) and potassium oxonate (1.5 g·kg⁻¹·d⁻¹) daily for 4 weeks. Serum uric acid, creatinine, total cholesterol (TCH), triglyceride and blood urea nitrogen (BUN) concentrations, as well as urinary uric acid and microalbuminuria were measured weekly. Serum xanthine oxidase (XOD) activity and renal histopathology were also evaluated. The renal expression of organic anion transporter 1 (OAT1) and organic anion transporter 3 (OAT3) was detected by western blot.
RESULTS: Si-Wu-Tang plus Er-Miao-San lowered serum uric acid, creatinine, triglyceride and BUN levels to a greater degree than did Si-Wu-Tang alone. Si-Wu-Tang plus Er-Miao-San ameliorated microalbuminuria and renal histopathology, as well as decreased serum TCH concentration and XOD activity in hyperuricemic rats. Combination of Si-Wu-Tang and Er-Miao-San also led to a greater increase in OAT1 and OAT3 expression than did Siwutang alone.
CONCLUSION: Si-Wu-Tang and Er-Miao-San synergistically ameliorated hyperuricemia and renal impairment in rats through upregulation of OAT1 and OAT3.
© 2015 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26509423     DOI: 10.1159/000438517

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  7 in total

1.  Pharmacologic targeting ERK1/2 attenuates the development and progression of hyperuricemic nephropathy in rats.

Authors:  Na Liu; Liuqing Xu; Yingfeng Shi; Lu Fang; Hongwei Gu; Hongrui Wang; Xiaoqiang Ding; Shougang Zhuang
Journal:  Oncotarget       Date:  2017-05-16

2.  Potential therapeutic effects of Cordyceps cicadae and Paecilomyces cicadae on adenine-induced chronic renal failure in rats and their phytochemical analysis.

Authors:  Ling Li; Tong Zhang; Chunru Li; Lu Xie; Ning Li; Tianling Hou; Yuqin Wang; Bing Wang
Journal:  Drug Des Devel Ther       Date:  2018-12-19       Impact factor: 4.162

3.  Effects of Chicory on Serum Uric Acid, Renal Function, and GLUT9 Expression in Hyperuricaemic Rats with Renal Injury and In Vitro Verification with Cells.

Authors:  Yong-Nan Jin; Zhi-Jian Lin; Bing Zhang; Yun-Fei Bai
Journal:  Evid Based Complement Alternat Med       Date:  2018-12-02       Impact factor: 2.629

4.  Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.

Authors:  Kei Nishizawa; Noriaki Yoda; Fumi Morokado; Hisakazu Komori; Takeo Nakanishi; Ikumi Tamai
Journal:  PLoS One       Date:  2019-04-05       Impact factor: 3.240

5.  Anti-Inflammatory Effects of Different Elution Fractions of Er-Miao-San on Acute Inflammation Induced by Carrageenan in Rat Paw Tissue.

Authors:  Xing Dai; Meihuizi Ding; Wei Zhang; Zihua Xuan; Juan Liang; Dongping Yang; Qiying Zhang; Bo Su; Housheng Zhu; Xiaoyi Jia
Journal:  Med Sci Monit       Date:  2019-10-23

Review 6.  Recent advances on uric acid transporters.

Authors:  Liuqing Xu; Yingfeng Shi; Shougang Zhuang; Na Liu
Journal:  Oncotarget       Date:  2017-08-10

7.  Effect and Mechanism of ShiZhiFang on Uric Acid Metabolism in Hyperuricemic Rats.

Authors:  Yansheng Wu; Yixing Wang; Jiaoying Ou; Qiang Wan; Liqiang Shi; Yingqiao Li; Fei He; Huiling Wang; Liqun He; Jiandong Gao
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-25       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.